GLENN DALE, Md. -- TVI Corporation, a global supplier of rapidly deployable first receiver and first responder systems for homeland security, hospitals, the military, police and fire departments, and public health agencies, announces it has received an order valued at more than $300,000 from the Veterans Affairs Healthcare System of Ohio (VISN 10) for TVIs surge capacity and pandemic preparedness suite of products. This order was placed through one of TVIs largest distributors.
The VA Healthcare System of Ohio is one of 21 Veterans Integrated Service Networks (VISN) designed to increase efficiency and improve integration of resources and service delivery. The overarching goal is to provide better patient-centered care.
We are pleased to see Ohios Veterans Administration (VA) investing in its healthcare preparedness, said TVI Corporations president and CEO, Richard V. Priddy. This order is representative of the high level of interest in our newest surge capacity and pandemic preparedness product suite. The addition of TVIs innovative technology will greatly enhance the existing emergency preparedness capabilities for VISN 10. Our surge capacity shelters will act as the first line of defense during a major incident throughout the Ohio VA system.
In the event of a natural disaster, terrorist activity, or industrial accident, the VISN 10 staff can utilize TVIs equipment to rapidly deploy surge capacity shelters, inoculation stations, decontamination, command and control, triage, and aid stations in strategic locations throughout the state of Ohio.
In the event of a pandemic outbreak, the VISN 10 staff will have the ability to deploy TVIs pneumatic shelters and inoculation stations in multiple locations throughout the state, and administer flu vaccines, antibiotics or other critical medicines that may ultimately save the lives of VA patients in Ohio.
Source: TVI Corporation
Â
Â
Our Understanding of Immune Issues Is Evolving: Here Are 5 Reasons Why
October 25th 2024The past 5 years in medicine have seen significant advances in RNA vaccines, understanding immune dysregulation, and improved interspecialty communication, promising better disease eradication and tailored treatments.